Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Parexel Completes Strategic Separation | Contract Pharma

What are you searching for?

Sign in
Breaking News

Parexel Completes Strategic Separation

Aims to simplify and streamline business strategy and customer relationships while positioning both organizations for long-term growth.

By: Contract Pharma

Contract Pharma Staff

Parexel, a provider of drug development servicess from clinical through commercialization, has completed the separation of its Parexel Informatics and Medical Imaging business. The strategic move aims to simplify and streamline Parexel’s business strategy and customer relationships while positioning both organizations for continued, long-term growth. As part of the separation, Parexel Informatics will become Calyx.
 
Parexel will continue to leverage Calyx’s Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), Interactive Response Technology (IRT) and Regulatory Information Management (RIM) solutions moving forward as part of the company’s clinical development offerings. Calyx will be privately held by the same ownership group that has owned Parexel since 2017.
 
“This announcement marks a significant milestone as we further position Parexel to expect accelerated growth and performance as a top-tier CRO,” said Jamie Macdonald, Chief Executive Officer of Parexel. “We believe the separation will provide Calyx the opportunity to prioritize investments in technology development, customer delivery and customer relationships while enabling the Parexel corporate business to strengthen its focus on the delivery of innovative clinical development solutions that reinforce our patients-first focus and advance world health.”
 
Calyx will be led by Chief Executive Officer Gavin Nichols and the company will be headquartered in Nottingham, UK, and Durham, NC. The new organization will employ approximately 2,300 employees.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics